Ultragenyx Pharmaceutical Inc. (RARE) analyst actions
Rating and price-target actions on RARE in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the RARE overview →
4 measured RARE analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out | Press release | -0.03% | -2.03% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out | Press release | -0.15% | -4.09% | |
| Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) | Press release | -0.05% | -0.03% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Reach Out | Press release | +0.20% | -0.76% |
Keep exploring
More RARE: earnings → · SEC filings → · RARE overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Quotient Limited - Ordinary Shares (QTNT) | 982 | -0.13% | 42% |
| PDL BIOPHARMA (PDLI) | 967 | 0.00% | 46% |
| QuidelOrtho Corporation (QDEL) | 965 | +0.02% | 50% |
| Recro Pharma, Inc. (REPH) | 965 | 0.00% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.